● neutral
Impact
PhasePhase 1
Time to marketUnknown — Phase 1 dosing only began June 2026; Phase 2 anticipated 2027, so approval (if trials succeed) is realistically many years away (early-to-mid 2030s).
MGL-2086 Updated Aug 2
What to watch
Do not trade MDGL on MGL-2086, there is no dated readout to trade; near-term price action will be driven by Rezdiffra's commercial ramp and the 2027 MAESTRO F4c cirrhosis outcomes readout. Watch for (1) any early Phase 1 SAD/MAD data release for MGL-2086 (likely 2027), (2) FDA feedback on the Rezdiffra/MGL-2086 Phase 2 combo design, and (3) progress of rival oral GLP-1s (notably Lilly's orforglipron, the molecule this is derived from), which caps the strategic upside.
Bull case
- Combining an oral GLP-1 with Rezdiffra could yield a once-daily, best-in-disease oral pill for MASH, Madrigal explicitly frames it that way, and a Phase 2 combo study with resmetirom is planned for 2027.
- Cheap optionality: exclusive global rights cost just $120M upfront (up to $2B in milestones plus royalties), and the mechanism is validated by the huge GLP-1 class, reducing mechanism risk.
- Execution is on schedule: Phase 1 SAD dosing initiated June 2026 as planned, and SAD/MAD data are expected to inform the Phase 2 design.
Bear case
- No clinical data yet, dosing only began June 2026; tolerability and efficacy of an oral GLP-1 specifically in MASH patients are unproven, and most early-stage GLP-1 programs never reach market.
- Brutal competition: MGL-2086 is an orforglipron derivative, and Lilly's orforglipron itself is far ahead in late-stage trials, while Novo's oral semaglutide is already approved, MGL-2086 would be a late entrant in a crowded oral-GLP-1 race.
- Long, expensive, risky road: Phase 2 anticipated 2027 at earliest, approval many years away, with up to $2B in milestone and royalty obligations owed to CSPC; Madrigal also booked a ~$117M one-time R&D charge for the license in Q3 2025.